🇺🇸 FDA
Pipeline program

Valemetostat Tosylate, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Valemetostat Tosylate

DS3201-330

Phase 2 small_molecule active

Quick answer

Valemetostat Tosylate, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Valemetostat Tosylate for Advanced or Metastatic Non-Small Cell Lung Cancer is a Phase 2 program (small_molecule) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Daiichi Sankyo Europe GmbH
Indication
Advanced or Metastatic Non-Small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials